Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dilaudid SR in Chronic Non-Malignant Pain
NCT00410644Phase 3Completed
- Sponsor
- ALZA Corporation
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, single-blind, single-arm trial of hydromorphone in chronic pain, sponsored by ALZA Corporation. Primary endpoints: Total daily dose of OROS hydromorphone, Daily use of rescue medication and 2 more. Status: completed.
02
Drugs
hydromorphone
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT00410644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410644.